JNPMEDI

JNPMEDI Inc. is a Korean startup founded in July 2020, with the goal of disrupting the healthcare industry through the integration of digital technologies into clinical research and trial operations. The company has recently launched Maven CDMS™ and Maven clinical cloud solutions, aiming to digitally transform the capabilities of regulatory authorities, pharmaceuticals, and CROs, thereby improving the execution, management, monitoring, and audit of clinical trials.

The team at JNPMEDI Inc. comprises c-suite officers with diverse experiences spanning management consulting, digital transformation strategy, cutting-edge tech development, clinical operations, and pharmaceuticals. This diverse expertise enables the company to understand both technologies and conventional clinical operations, delivering high performance to clinical environments and ultimately benefitting people worldwide. The company operates across R&D laboratory, business development, consulting, and clinical operation support divisions.

On 22 November 2022, JNPMEDI Inc. secured a significant KRW14.00B Series A investment from a group of prominent investors, including Kakao Ventures, Aju IB Investment, Murex Partners, Pavilion Capital, and Gentium Holdings.

The company's slogan, "Everyday Digital Partner to Researches & Clinical Trials," underscores its commitment to leveraging digital technologies to advance the healthcare industry. Positioned within the health care sector, JNPMEDI Inc. is a promising player in the digital transformation of clinical research and trials.